Ashwath Jayagopal - Opus Genetics, Chief Officer
| IRD Stock | 1.03 0.01 0.96% |
Executive
Ashwath Jayagopal is Chief Officer of Opus Genetics,
| Age | 43 |
| Address | 37000 Grand River Avenue, Farmington Hills, MI, United States, 48335 |
| Phone | 248 957 9024 |
| Web | https://opusgtx.com |
Ashwath Jayagopal Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ashwath Jayagopal against Opus Genetics, stock is an integral part of due diligence when investing in Opus Genetics,. Ashwath Jayagopal insider activity provides valuable insight into whether Opus Genetics, is net buyers or sellers over its current business cycle. Note, Opus Genetics, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Opus Genetics,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ashwath Jayagopal over two weeks ago Disposition of 5193 shares by Ashwath Jayagopal of Opus Genetics, at 1.15 subject to Rule 16b-3 | ||
Ashwath Jayagopal over three months ago Acquisition by Ashwath Jayagopal of 75000 shares of Ocuphire Pharma subject to Rule 16b-3 |
Opus Genetics, Management Efficiency
The company has Return on Asset of (0.3895) % which means that on every $100 spent on assets, it lost $0.3895. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.643) %, meaning that it generated no profit with money invested by stockholders. Opus Genetics,'s management efficiency ratios could be used to measure how well Opus Genetics, manages its routine affairs as well as how well it operates its assets and liabilities. As of March 1, 2025, Total Assets is expected to decline to about 40.3 M. Non Current Assets Total is expected to grow at the current pace this yearSimilar Executives
| Found 8 records | EXECUTIVE Age | ||
| Gina Kay | Transcontinental Realty Investo | N/A | |
| Beth Blankenship | National Health Investors | N/A | |
| Kevin Shannon | Inflection Point Acquisition | 30 | |
| Susan Sidwell | National Health Investors | N/A | |
| Peter Ondishin | Inflection Point Acquisition | 37 | |
| Michelle Kelly | National Health Investors | N/A | |
| Kristin Gaines | National Health Investors | 53 | |
| Bradley Kyles | Transcontinental Realty Investo | N/A | |
Management Performance
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.39 |
Opus Genetics, Leadership Team
Elected by the shareholders, the Opus Genetics,'s board of directors comprises two types of representatives: Opus Genetics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opus. The board's role is to monitor Opus Genetics,'s management team and ensure that shareholders' interests are well served. Opus Genetics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opus Genetics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph MBA, Chief Officer | ||
| Bernhard MBA, Senior Secretary | ||
| Ashwath Jayagopal, Chief Officer | ||
| Bindu Manne, Head Commercialization | ||
| MAcc CPA, Senior Finance | ||
| Nirav CFA, Chief Officer | ||
| Erik Sims, Director Controller | ||
| MBA MD, CEO Director |
Opus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opus Genetics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (2.07) % | ||||
| Current Valuation | (962.64 K) | ||||
| Shares Outstanding | 31.57 M | ||||
| Shares Owned By Insiders | 16.14 % | ||||
| Shares Owned By Institutions | 16.63 % | ||||
| Number Of Shares Shorted | 672.99 K | ||||
| Price To Book | 1.04 X | ||||
| Price To Sales | 4.26 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Opus Genetics, is a strong investment it is important to analyze Opus Genetics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Opus Genetics,'s future performance. For an informed investment choice regarding Opus Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Opus Genetics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics,. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 0.337 | Quarterly Revenue Growth (0.68) | Return On Assets (0.39) | Return On Equity |
The market value of Opus Genetics, is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics,'s value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics,'s market value can be influenced by many factors that don't directly affect Opus Genetics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.